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Elsa J Kracke1* and Aneesh K Tosh2Abstract
Introduction: There are currently few studies focusing on the efficacy of long-term atypical antipsychotics to treat
anorexia nervosa in the pediatric population.
Case description: This case report follows the treatment of a 17 year-old female with anorexia nervosa over her
four-year undergraduate career. After two years of multidisciplinary treatment, low-dose risperidone was initiated
due to persistence of her disease. She expressed decreased rigidity around meal times, her weight improved and she
had resumption of menses. She was compliant with treatment through graduation and maintained her weight gain.
Discussion & evaluation: Atypical antipsychotics are a treatment option in the management of anorexia nervosa.
Risperidone has not been studied as frequently as olanzapine for eating disorders. Risperidone was chosen for its more
favorable side effect profile and decreased cost to the patient. Previous studies on anorexia nervosa treatment have
occurred during inpatient treatment and have limited follow-up due to patients’ refusal to initiate or maintain medication
compliance. This case presents 17 months of outpatient data. The efficacy of risperidone therapy was evaluated with
frequent weight checks, subjective decrease in rigidity, serial complete metabolic panels, and restoration of menses.
Conclusions: In this case report, an adolescent female treated with low-dose risperidone had decreased rigid thinking,
weight gain and resolution of secondary amenorrhea without medication side effects. Therefore, the atypical
antipsychotic risperidone may be an effective long-term outpatient treatment option for patients with anorexia nervosa.
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Anorexia nervosa (AN) restricting subtype is defined as
an individual that loses weight through dieting, fasting
and/or excessive exercise over at least a three-month
consecutive period. Characteristics of AN, such as the
intense fear of gaining weight, disturbance in the percep-
tion of body shape and denial of the seriousness of ex-
tremely low body weight, have been compared to the signs
of rigidity in psychosis and inflexibility of delusional disor-
ders. Comorbid depression is also often seen in patients
with AN. Therefore, atypical antipsychotics that act on
both 5-HT and dopamine receptors have recently been
studied to monitor improvements in behavior and weight
gain (Hagman et al. 2011). In addition, the minimal sedat-
ing effects of atypical antipsychotics may benefit patients
that have concomitant anxiety, and could reduce or* Correspondence: ejktxf@health.missouri.edu
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in any medium, provided the original work is preplace the use of SSRIs in the treatment of AN. Antide-
pressants have not been successful for weight gain in AN,
yet are used to treat associated co-morbid conditions such
as depression and anxiety. Current literature focuses pri-
marily on short-term olanzapine use in patients with AN
while they are admitted for inpatient therapy. This case re-
port is a unique presentation of a female with AN that ac-
complished weight restoration with resumption of menses
after long-term treatment with risperidone completely in
an outpatient setting.Case description
This case report follows the four-year treatment of patient
that presented at the beginning of her freshman year of
college to a university health clinic with an established
diagnosis of anorexia nervosa. She was initially diagnosed
in January 2008, at 17 years of age. Her premorbid weight
was 50 kg. Her menses previously had cycle length irregu-
larity, however April 2008 marked her last menstruals is an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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http://www.springerplus.com/content/3/1/706period. When she presented for her first visit to the health
center on August 18, 2008, she weighed 41.36 kg at a
height of 172.72 cm (BMI 13.8 kg/m2) and had developed
secondary amenorrhea. Her eating disorder initially started
by restricting fats, and progressed to eliminating all fats
and then overall calories. These characteristics are consist-
ent with AN restrictive subtype. The patient did not report
purging, laxative abuse or excessive exercising to compen-
sate for calorie intake. Although she played competitive
tennis in high school, she reduced her activity level during
college considerably.
She noted anxiety and fatigue in review of systems,
and denied signs of depression. No significant past med-
ical history, surgical history or family history, including
history of eating disorders or other psychiatric condi-
tions, was mentioned during her treatment. Her medica-
tion list when she presented consisted of escitalopram
for anxiety, doxycycline for acne, a generic multivitamin
and a fish oil supplement. Significant findings on initial
physical exam were a thin-appearing female with lanugo.
Vital signs revealed sinus bradycardia with a heart rate
of 56 bpm, blood pressure 102/60, temperature 97.3 F
and BMI of 13.8 kg/m2.
Treatment course
The patient presented in August 2008 at 41.36 kg
already taking escitalopram 20 mg. In the 24 days fol-
lowing her presentation, she proceeded to lose weight
until she reached 39.32 kg (BMI 13.2 kg/m2). At this
time, the multidisciplinary medical team made the deci-
sion for her to enter residential treatment at an outside
eating disorder treatment facility. After 3 months of
structured inpatient treatment, her weight increased to
47.73 kg, and she was able to enroll in classes for the
spring semester. Over the next 10 months she had no
significant improvement in weight or mealtime anxiety.
Escitalopram was discontinued and replaced with sertra-
line at 50 mg. The dose of sertraline gradually increased
from 50 mg to 75 mg to 100 mg and then to a maximum
of 150 mg over a one-year period to treat her anxiety.
Throughout this time, the patient still had subjective feel-
ings of anxiety and rigidity at meal times and therefor did
not have significant improvement in weight gain. On
November 29, 2010, at a weight of 46.64 kg, she agreed
to begin a low-dose atypical antipsychotic, risperidone
0.25 mg. Approximately 3 months later, she had gained
only1.36 kg and reported no medication side effects, so
the dose of risperidone was increased to 0.5 mg. After
seven months of compliance at this dose, she gained an-
other 6 kg and was able to decrease her sertraline dose
to 100 mg.
Lab work during the two years from initial presenta-
tion to the addition of risperidone (2008–2010) showed
a complete metabolic panel within normal limits and anormal vitamin D level at 37 ng/mL. Electrocardiogram
showed sinus bradycardia without QTc prolongation.
Complete metabolic panel, fasting lipid panel and prolactin
lab values two years after starting risperidone continued to
be within normal limits (Table 1), and electrocardiogram
showed sinus rhythm without QTc prolongation.
In December 2011, she had resumption of menses at a
weight of 54.09 kg (BMI 18.1 kg/m2). Her weight re-
mained stable, and the last weight recorded in April 2012
was 52.09 kg (BMI 17.5 kg/m2) (Figure 1, Table 2). Her
care was transferred after graduation from university, and
she continues to remain in recovery.
Discussion and evaluation
This case presents a patient with anorexia nervosa that
was treated over the course of her four-year undergradu-
ate career primarily in an outpatient setting. After two
years of multidisciplinary treatment with a physician, a
dietitian, a therapist and taking an SSRI, she decided to
start risperidone. Although many studies have focused
on olanzapine for weight gain, risperidone was chosen
for its more favorable side effect profile and the signifi-
cant decreased cost to the patient. The patient’s lab work
remained within normal limits after initiating treatment,
suggesting a low dose atypical antipsychotic could pro-
vide the benefit of gradual weight gain without meta-
bolic consequences. Reduced cost to the patient may not
only increase compliance and initial willingness to try
the medication, but also justifies the use of risperidone
instead of olanzapine as a long-term therapy to maintain
weight gain and reach a recovery phase.
Near the end of her treatment, after resumption of men-
ses, the patient was queried as to why she felt the risperi-
done was helpful in her recovery. The patient felt that she
had a significant improvement in rigidity during meal
times after starting the risperidone. Despite having similar
motivation to improve her nutrition in the past, the rigid-
ity was a barrier that she was not able to overcome until
the reperidone was started. Also, it is well known that
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Figure 1 Weight gain throughout four-year treatment period.
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http://www.springerplus.com/content/3/1/706her metabolic labs were normal and stable during her
treatment, the possibility that weight gain as a side effect
of risperidone contributed to her resumption of menses is
another conceivable factor in her recovery. Therefore, a
combination of factors related to the risperidone likely
played a role in the patient’s recovery.
This case is unique because the patient had good insight
and was motivated to gain weight, resulting in strict com-
pliance with her medical treatment. The patient was
highly motivated to attend college and had strong support














4/27/12 52.09treated in the eating disorders clinic. However, these im-
pressions are subjective. Therefore, one limitation to this
report is that personal events throughout this patient’s
undergraduate experience that may have influenced her
improved health are not quantifiable. Previous studies fo-
cused on treating AN tend to be limited due to the ego-
syntonic quality of AN and the refusal to start or maintain
treatment for fear of weight gain as a medication side ef-
fect (Balestrieri et al. 2013). For this reason, replicating the
compliance and success demonstrated in this case report
might be difficult in a patient unmotivated to gain weight.Event
First clinic visit
Inpatient treatment at an outside treatment facility (88 days)
Escitalopram 20 mg
Discontinued escitalopram, started sertraline 25 mg
Increased sertraline 50 mg
Increased sertraline 75 mg
Increased sertraline 100 mg
Increased sertraline 150 mg
Started risperidone 0.25 mg, continued sertraline 150 mg
Risperidone increased to 0.5 mg, continued sertraline 150 mg
Sertraline decreased to 100 mg, continued risperidone 0.5 mg
Restoration of menses
Last clinic visit
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done long-acting injection may be another beneficial alter-
native (Umehara et al. 2014). Not only was this patient
able to gain weight with risperidone, she experienced de-
creased rigidity around meal times and was able to de-
crease her SSRI dose for anxiety. Previously published
studies, with one exception (Hagman et al. 2011), have not
treated AN with concomitant SSRI and atypical antipsy-
chotics, and this is the only report to our knowledge of
decreasing the SSRI dose during the treatment period. Re-
sumption of menses after one year on risperidone was an-
other measure of improvement that has been mentioned
only one time previously in the literature (Newman-Toker
2000). The patient had experienced secondary amenorrhea
for 3 years and 8 months before the return of her menses.
This case also represents the longest published treatment
with an atypical antipsychotic, 17 months, in addition to
being completely in an outpatient setting. Therefore, ris-
peridone may become a feasible and effective outpatient
option for patients with AN. She experienced no side ef-
fects from her medications, and when asked which therapy
helped her the most, she contributed her successful weight
gain to risperidone.
Conclusions
This case report demonstrates that the atypical anti-
psychotic risperidone could be a safe and effective option
for adolescent patients with anorexia nervosa motivated to
gain weight. Ideally, the next steps would be to recruit
more patients with anorexia nervosa to participate in a
randomized controlled trial to determine the efficacy of
multidisciplinary therapy with risperidone or placebo in
the outpatient setting. As previously mentioned, recruiting
patients with anorexia nervosa interested in participating
in studies on therapy options is challenging.
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